received by the International Bureau on 26 March 2020 (26.03.2020)

What is claimed is:

1. A method of delivering a therapeutic agent to a patient’s brain, comprising:

administering a solution containing a ferromagnet to a patient’s blood stream;

applying a magnetic field to a targeted region of the patient’s brain;

affecting the ferromagnet with the magnetic field at the targeted region to facilitate delivery of the therapeutic agent to the patient’s brain; and

administering the therapeutic agent to the patient’s blood stream, wherein the

therapeutic agent enters the patient’s brain at the targeted region.

2. The method of claim 1, wherein affecting the feiromagnet with the magnetic field (i) forms an opening in the blood-brain barrier (BBB) at the targeted region, or (ii) increases local perfusion at the targeted region.

3. The method of claim 2, wherein the step of administering the therapeutic agent occurs after both (i) opening the BBB at the targeted region, and (ii) increasing local perfusion at the targeted region.

4. The method of claims 2 or 3, wherein increasing local perfusion is temporary.

5. The method of any of claims 1 to 4, wherein the targeted region of the patient’s brain is associated with a disease condition.

6. The method of claim 5, wherein the disease condition is associated with a disease selected from the group consisting of a learning disorder, an anxiety disorder, a motor disorder, a consciousness disorder, a movement disorder, an attention disorder, a stroke, a vascular disease, dementia, progressive dementia, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cancer, schizophrenia, depression, developmental disorder, substance abuse, and traumatic brain injury.

7. The method of any of claims 1 to 6, wherein the targeted region of the patient’s brain is selected from the group consisting of frontal lobe, parietal lobe, occipital lobe, temporal lobe, hippocampus, hypothalamus, brain stem, cerebellum, amygdala, corticospinal tract, thalamus, substantia nigra, basal ganglia, Heschl’s gyrus, a tumor, a lesion, necrotic tissue, and a point of injury.

8. The method of any of claims 1 to 7, wherein the therapeutic agent is selected from the group consisting of a chemical, a molecule, a drug, or a biological product.

9. The method of any of claims 1 to 8, further comprising administering a plurality of therapeutic agents comprising therapeutic agents of more than one type or derivation.

10. The method of any of claims 1 to 9, wherein the therapeutic agent is synthetic.

11. The method of any of claims 1 to 10, wherein the fenomagnet is selected from the group consisting of Co, Fe, Fe2O3, FeOFe2O3, NiOFe2O3, CuOFe2O3, MgOFe2O3, MnBi, Ni, MnSb, MnOFe2O3, Y3Fe5012, CrO2, MnAs, Gd, Tb, Dy, EuO, and alloys thereof.

12. The method of any of claims 1 to 11, wherein the targeted region of the patient’s brain is of therapeutic interest.

13. The method of any of claims 1 to 12, wherein the step of affecting the fenomagnet with the magnetic field is performed for at least 5 minutes.

14. The method of any of claims 1 to 13, wherein the magnetic field is applied using a transcranial magnetic stimulation (TMS) device, and wherein the magnetic field vibrates or spins the fenomagnet.

15. The method of any of claims 1 to 14, wherein the solution further contains a plurality of ferromagnets comprising ferromagnets of more than one type or size.

16. The method of any of claims 1 to 15, further comprising the step of applying a second magnetic field to affect a second fenomagnet located at a second targeted region of the patient’s brain.

17. A method of treating a patient comprising using a transcranial magnetic stimulation (IMS) device to facilitate delivery of a therapeutic agent to a patient’s brain through the blood-brain barrier (BBB) by at least one of (i) opening the patient’s BBB within the targeted region or (ii) increasing local perfusion within the region.

18. The method of claim 17, further comprising a first step of administering the therapeutic agent to the patient and using the TMS device to affect a fenomagnet located in a targeted region of the patient’s brain followed by a second step of using the TMS device to affect the ferromagnet located in the targeted region, wherein the first step and second step are separated by less than 20 minutes.

19. The method of claim 18, wherein affecting the ferromagnet both (i) opens the patient’s BBB within the targeted region and (ii) increases local perfusion within the region.

20. The method of any of claims 17 to 19, further comprising the step of administering the therapeutic agent to the patient.